{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-035979","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.184204+00:00","generated_at":"2026-06-09T01:58:56.688738+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Corcept Q3 revenue $123.6M (+22% YoY); raises FY 2023 guidance to $470-$480M","bullets":["Revenue $123.6M (+22% YoY); net income $31.4M ($0.28 diluted EPS) vs $34.6M ($0.30) in Q3 2022.","FY 2023 revenue guidance raised to $470-$480M from previous $455-$470M.","Cash and investments $414.8M at Sept 30, up from $363.3M end of prior quarter.","GRACE Phase 3 enrollment complete; NDA for relacorilant in Cushing's expected Q2 2024.","Key 2024 trial readouts: GRADIENT (mid-2024), ROSELLA, DAZALS (year-end 2024), CATALYST prevalence (Q1 2024)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-035979","json":"https://secwatch.observer/filing/0001628280-23-035979.json","markdown":"https://secwatch.observer/filing/0001628280-23-035979.md","text":"https://secwatch.observer/filing/0001628280-23-035979.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000162828023035979/0001628280-23-035979-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000162828023035979/cort-20231101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T01:58:56.688738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"515200335d34855b991eac5fee48dfdb726a8f6e","claim":"CORCEPT THERAPEUTICS INC reported the quarter ended September 30, 2023 results: revenue $123.6 million, net income $31.4 million, EPS $0.28 (diluted). Guidance raised.","evidence_excerpt":"and neurology disorders by modulating the effects of the hormone cortisol, today reported results for the quarter ended September 30, 2023. Financial Results • Revenue of $123.6 million, a 22 percent increase from third quarter 2022 • Increase in 2023 revenue guidance to $470 – $480 million, from $455 – $470 million • Net income per common share of $0.28","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1088856/000162828023035979/0001628280-23-035979-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$123.6 million"},{"label":"Net income","value":"$31.4 million"},{"label":"EPS","value":"$0.28 (diluted)"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}